Shandong New Time Pharmaceutical Co., LTD
Registry sponsor category
Industry
- Other names
- Shandong New Time Pharmaceutical Co., LTD
- Company name
- Shandong New Time Pharmaceutical Co., LTD
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (34)
- A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
- A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors
- A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
- A Phase Ⅱ Study of F520 in Patients With Urothelial Carcinoma
- A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction
- A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL
- A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)
- A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
- A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis
- A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents
- A Phase IV Study of Huazhi Rougan Granule
- A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver
- A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
- A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
- Bioequivalence Study of Dronedarone Hydrochloride Tablets
- Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting Conditions
- Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans
- Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans